Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

The disclosure provides methods for treating vulvovaginal atrophy (WA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

The disclosure provides methods for treating vulvovaginal atrophy (WA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

The present invention provides methods for treating inflammatory or autoimmune disease using calcitonin receptor activators, such as calcitonin receptor activating antibodies, among others. The invention also features compositions containing calcitonin receptor activators, methods of diagnosing patients with calcitonin receptor-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with calcitonin receptor activators.

Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.